Business Description
ISIN : US05463X1063
Share Class Description:
AXGN: Ordinary SharesTotal Employee Number:
622Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.55 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.99 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 31.71 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.1 | |||||
3-Year FCF Growth Rate | 51.1 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 52.97 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 21.19 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.16 | |||||
9-Day RSI | 47.46 | |||||
14-Day RSI | 51.48 | |||||
3-1 Month Momentum % | 8.42 | |||||
6-1 Month Momentum % | 57.29 | |||||
12-1 Month Momentum % | 198.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.6 | |||||
Quick Ratio | 5.04 | |||||
Cash Ratio | 3.67 | |||||
Days Inventory | 243.43 | |||||
Days Sales Outstanding | 42.84 | |||||
Days Payable | 16.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -4.22 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.56 | |||||
Operating Margin % | -5.12 | |||||
Net Margin % | -13.36 | |||||
EBITDA Margin % | -8.08 | |||||
FCF Margin % | 2.59 | |||||
OCF Margin % | 5.99 | |||||
ROE % | -19.44 | |||||
ROA % | -13.55 | |||||
ROIC % | -7.91 | |||||
3-Year ROIIC % | 51.45 | |||||
ROC (Joel Greenblatt) % | -19.31 | |||||
ROCE % | -13.29 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 67.62 | |||||
PE Ratio without NRI | 127.07 | |||||
PS Ratio | 9.64 | |||||
PB Ratio | 10.11 | |||||
Price-to-Tangible-Book | 10.41 | |||||
Price-to-Free-Cash-Flow | 380.2 | |||||
Price-to-Operating-Cash-Flow | 163.13 | |||||
EV-to-EBIT | -85.25 | |||||
EV-to-EBITDA | -123.41 | |||||
EV-to-Forward-EBITDA | 97.35 | |||||
EV-to-Revenue | 9.97 | |||||
EV-to-Forward-Revenue | 7.33 | |||||
EV-to-FCF | 384.72 | |||||
Price-to-GF-Value | 2.78 | |||||
Price-to-Median-PS-Value | 1.86 | |||||
Price-to-Graham-Number | 7.66 | |||||
| Price-to-Net-Current-Asset-Value | 17.06 | |||||
| Price-to-Net-Cash | 41.27 | |||||
Earnings Yield (Greenblatt) % | -1.17 | |||||
FCF Yield % | 0.25 | |||||
Forward Rate of Return (Yacktman) % | -30.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AXGN
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Axogen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 251.174 | ||
| EPS (TTM) ($) | -0.68 | ||
| Beta | 2.1455 | ||
| 3-Year Sharpe Ratio | 0.98 | ||
| 3-Year Sortino Ratio | 1.99 | ||
| Volatility % | 49.48 | ||
| 14-Day RSI | 51.48 | ||
| 14-Day ATR ($) | 2.298507 | ||
| 20-Day SMA ($) | 49.32625 | ||
| 12-1 Month Momentum % | 198.44 | ||
| 52-Week Range ($) | 15.2701 - 52.91 | ||
| Shares Outstanding (Mil) | 53.76 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axogen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Axogen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 08:00 | In 173 days | ||
| Annual report for 2026 | 2027-02-24 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 172 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 08:00 | In 55 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 54 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | 41.15 (-1.09%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 41.15 (-1.09%) | ||
| General meeting for 2026 | 2026-06-23 08:30 | 44.95 (+0.27%) | ||
| Guidance call for 2026 | 2026-05-13 09:35 | 40.93 (+0.17%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:00 | 39.39 (-0.35%) |
Axogen Inc Frequently Asked Questions
Guru Commentaries on NAS:AXGN
We introduced Axogen as an optionality position, as it provides nerve grafts used for peripheral nerve repair. Following BLA approval of their Avance nerve allograft and related positive momentum in insurance coverage, we think Axogen is highly asymmetric to a future where nerve repair becomes standard-of-care, including for patients undergoing a mastectomy or prostatectomy.
Axogen, Inc. is a leader in the development of technologies focused on peripheral nerve regeneration and repair. The company’s biologically active nerve graft platform reduces procedural risks by eliminating the need for secondary surgical sites. During the quarter, Axogen reported top-line growth of 17% and reaffirmed its full-year guidance for both revenue growth and gross margin. Despite a decline in shares due to a weaker-than-expected Q1 gross margin of 72%, we believe the ramp-up of Axogen’s new manufacturing facility positions the company for long-term margin expansion, with the potential to exceed 80% gross margins. Given our conviction in the operational improvement expected in the second half of the year, we added to our position during the period.
Axogen, Inc. specializes in providing surgical solutions to restore nerve function and quality of life for patients with nerve damage. However, the company faced challenges as its stock declined after missing on earnings and announcing an inventory write-down. This write-down was attributed to customers delaying purchases while awaiting improved solutions related to Axogen's biologics license application. Despite these setbacks, we believe that Axogen’s technologies will continue to gain wide uptake among surgeons.
Press Release
Articles on Axogen Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
